University of Aberdeen logo

AURA - Aberdeen University Research Archive

 

Persistent Reductions in OCS Use in Patients With Severe, OCS-Dependent Asthma Treated With Dupilumab : LIBERTY ASTHMA TRAVERSE Study

Simple item page
dc.contributor.authorGurnell, Mark
dc.contributor.authorDomingo, Christian
dc.contributor.authorRabe, Klaus F
dc.contributor.authorMenzies-Gow, Andrew
dc.contributor.authorPrice, David
dc.contributor.authorBrusselle, Guy
dc.contributor.authorWechsler, Michael E
dc.contributor.authorXia, Changming
dc.contributor.authorDjandji, Michel
dc.contributor.authorGall, Rebecca
dc.contributor.authorJacobNara, Juby A.
dc.contributor.authorRowe, Paul J.
dc.contributor.authorDeniz, Yamo
dc.contributor.authorSiddiqui, Shahid
dc.contributor.institutionUniversity of Aberdeen.Institute of Applied Health Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Other Applied Health Sciencesen
dc.date.accessioned2024-08-21T10:40:01Z
dc.date.available2024-08-21T10:40:01Z
dc.date.issued2022-09
dc.descriptionAcknowledgments and funding sources Data first presented at the 118th International Conference of the American Thoracic Society (ATS 2022); San Francisco, CA, USA; May 13–18, 2022. Research sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. ClinicalTrials.gov Identifiers: NCT02528214 (VENTURE)/NCT02134028 (TRAVERSE). Medical writing/editorial assistance was provided by Anthony Aggidis, PhD, of Excerpta Medica, and was funded by Sanofi and Regeneron Pharmaceuticals, Inc., according to the Good Publication Practice guideline. Alternate presenters: Anne Atenhan and Mayank Thakur.en
dc.description.statusPeer revieweden
dc.format.extent145035
dc.identifier292677341
dc.identifier308240f8-0e89-44d3-bae8-6c50a6f52ba9
dc.identifier.citationGurnell, M, Domingo, C, Rabe, K F, Menzies-Gow, A, Price, D, Brusselle, G, Wechsler, M E, Xia, C, Djandji, M, Gall, R, JacobNara, J A, Rowe, P J, Deniz, Y & Siddiqui, S 2022, 'Persistent Reductions in OCS Use in Patients With Severe, OCS-Dependent Asthma Treated With Dupilumab : LIBERTY ASTHMA TRAVERSE Study', Allergo Journal International, vol. 31, no. 6, P4.03, pp. 212. https://doi.org/10.1007/s40629-022-00225-6en
dc.identifier.doi10.1007/s40629-022-00225-6
dc.identifier.iss6en
dc.identifier.issn2197-0378
dc.identifier.urihttps://hdl.handle.net/2164/24079
dc.identifier.vol31en
dc.language.isoeng
dc.relation.ispartofAllergo Journal Internationalen
dc.subjectR Medicineen
dc.subject.lccRen
dc.titlePersistent Reductions in OCS Use in Patients With Severe, OCS-Dependent Asthma Treated With Dupilumab : LIBERTY ASTHMA TRAVERSE Studyen
dc.typeJournal itemen

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Gurnell_etal_DAK_Persistent_Reductions_IN_AAM.pdf
Size:
141.64 KB
Format:
Adobe Portable Document Format
Download

Collections

All research